The Pharma companies focusing on oncology has been emerging in market with greater needs of people suffering from Cancer. The sales of oncology drugs gradually increasing with diseases. The top oncology companies are now developing more advanced, effective, and tolerable drugs to improve treatment outcomes and the patient experience. Roche proved to be on top 10 list of Oncology companies. Our team at PharmaShots has compiled a list of top 10 pharma companies based on their 2018 total revenue.
Total Revenue: $32.73B Total Employees: ~30,000
Oncology Segment Revenue: $3.93B Pharma Segment Revenue: $32.73B
Founded Year: 1900 Headquarter: Illinois, United States
Market Cap: ~$114.73B Stock Exchange: NYSE
AbbVie is a global, research-based biopharmaceutical company that develops therapies majorly for Chronic Autoimmune Diseases, Oncology, Virology with additional targets like cystic fibrosis and women’s health. In Apr’18, AbbVie initiated P-III trial for the combination therapy of Imbruvica + Venclexta vs chlorambucil plus Gazyva (obinutuzumab) to treat 1L chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). AbbVie’s key product Humira (adalimumab) is a biologic therapy and is approved in the US, Canada, Mexico, and EU. In Dec’18, AbbVie pact a deal with Lupin to develop novel therapies for cancer.
9. ELI LILLY
Total Revenue: $24.55B Total Employees: ~38,680
Oncology Segment Revenue: $4.26B Pharma Segment Revenue: $22.93B
Founded Year: 1901 Headquarter: Indiana, United States
Market Cap: ~$112.52B Stock Exchange: NYSE
Eli Lilly and Company is a global pharmaceutical firm focused on delivering therapies in two divisions Human Pharmaceutical products and Animal Health products. The pharmaceutical portfolio offers products for Cardiovascular, Endocrinology, Immunology, Neuroscience, and Oncology. In Q4’18, Lilly’s Verzenio was approved in Japan and EU for metastatic breast cancer. In 2018 Lilly expanded its oncology portfolio by acquisition of Loxo Oncology.
Total Revenue: $22.09B Total Employees: ~50,000
Oncology Segment Revenue: $6.02B Pharma Segment Revenue: $21.04B
Founded Year: 1999 Headquarter: Cambridge, United Kingdom
Market Cap: ~$51.5B Stock Exchange: NYSE
AstraZeneca is a global, biopharmaceutical company focusing on Oncology, Respiratory, Neurology, Autoimmune and other therapy areas. In Dec’18 AstraZeneca and Merck’s Lynparza (olaparib) received FDA’s approval as 1L treatment for BRCA-Mutated Advanced Ovarian Cancer. In early 2018 AstraZeneca granted Innate Pharma the commercialization rights for Lumoxiti in the US and EU. The company also has the PD molecule Imfinzi, an approved product for bladder and lung cancer.
Total Revenue: $53.64B Total Employees: ~92,400
Oncology Segment Revenue: $7.20B Pharma Segment Revenue: $53.64B
Founded Year: 1849 Headquarter: New York, United States
Market Cap: ~$232.96B Stock Exchange: NYSE
Pfizer is a research-based, global biopharmaceutical company having a vast portfolio including Oncology, Medicines, Vaccine and other health care products for the prevention & treatment of untreated diseases. In 2018, Pfizer’s leading Oncology drugs Vizimpro (dacomitinib), Talzenna (talazoparib) and Lorbrena (lorlatinib) received FDA’s approvals for NSCLC, Breast Cancer and ALK+ NSCLC respectively.
6. MERCK & CO.
Total Revenue: $42.29B Total Employees: ~69,000
Oncology Segment Revenue: $8.24B Pharma Segment Revenue: $42.29B
Founded Year: 1891 Headquarter: New Jersey, United States
Market Cap: ~$205.15B Stock Exchange: NYSE
Merck & Co. is a global health care company delivering innovative health care products with its Prescription medicines, Oncology drugs, Vaccines, Biologic therapies and Animal Health care products. In Mar’18, Merck and Eisai signed worldwide collaboration for the co-development and co-commercialization of Eisai’s Lenvima. Merck has numerous successful therapies in its portfolio including Keytruda with net sales of $7.17B in 2018 and has 900+ trials for Keytruda including 600+ in oncology
5. JOHNSON & JOHNSON
Total Revenue: $81.58B Total Employees: ~135,100
Oncology Segment Revenue: $9.84B Pharma Segment Revenue: $40.73B
Founded Year: 1887 Headquarter: New Jersey, United States
Market Cap: ~$350.76B Stock Exchange: NYSE
Johnson & Johnson (J&J) is an American multinational medical device, pharmaceutical, and consumer packaged goods manufacturing company. The pharmaceutical department of the company focuses on Immunology, Oncology, Infectious Diseases and Vaccines, Neuroscience, Cardiovascular and Metabolism and the medical device sector is focused on Orthopedics and Cardiovascular Disease solutions. Johnson’s Oncology portfolio generated total revenue of $9.8B in 2018 exceeding 35.6% to 2017.
4. BRISTOL-MYERS SQUIBB
Total Revenue: $22.56B Total Employees: ~23,300
Oncology Segment Revenue: $10.31B Pharma Segment Revenue: $22.56B
Founded Year: 1989 Headquarter: New York, United States
Market Cap: ~$75.05B Stock Exchange: NYSE
Bristol-Myers Squibb is an American pharmaceutical company focused on Oncology, Cardiovascular, Immuno-Science, and Fibrosis. Its blockbusters drug Opdivo (nivolumab) used for cancer has generated sales of $6.7B in 2018. In Dec’18 the company collaborated with Vedanta Biosciences for the development of combination therapies for Advanced or Metastatic Cancers. BMS acquired Celgene in 2019 to strengthen its portfolio of Oncology, Immunology, Inflammation, and Cardiology.
Total Revenue: $51.9B Total Employees: ~125,161 Employees
Oncology Segment Revenue: $13.42B Pharma Segment Revenue: $42.3B
Founded Year: 1996 Headquarter: Basel, Switzerland
Market Cap: ~$216.96B Stock Exchange: SIX Swiss Exchange, NYSE
Novartis is a multinational group of companies specializing in the research, development, manufacture and marketing drugs which is divided into two categories: Novartis Oncology and Novartis Pharmaceuticals. The Oncology portfolio offers drugs in areas of Cancer and Hematologic disorders. While the pharma portfolio offers in Ophthalmology, Neuroscience, Immunology, Hepatology including Dermatology and Respiratory. In Dec’18 the company acquired Endocyte to strengthen its portfolio of nuclear medicine and radioligand therapy used for treating cancer.
Total Revenue: $15.42B Total Employees: ~16,962
Oncology Segment Revenue: $13.65B Pharma Segment Revenue: $15.26B
Founded Year: 1986 Headquarter: New Jersey, United States
Market Cap: ~$66.70B Stock Exchange: NASDAQ
Celgene is an integrated global biopharmaceutical company focused on developing therapies in Oncology, Immunology, Hematology, and Inflammatory Diseases. Celgene’s one of the leading Cancer drug Revlimid is in P-III trials including Otezla, is evaluated in patients with r/r follicular or marginal zone lymphoma & Behcet’s disease respectively. Additionally, in 2018 Celgene expanded its collaboration with Dragonfly for Solid and Hematological Cancers. In 2019, Celgene is acquired by BMS for $74B.
Total Revenue: $56.91B Total Employees: ~92,400
Oncology Segment Revenue: $26.06B Pharma Segment Revenue: $44.10B
Founded Year: 1849 Headquarter: New York, United States
Market Cap: ~$226.50B Stock Exchange: NYSE
Roche Holding AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Roche’s Oncology portfolio is currently focusing on Breast, Bladder, Cervical, Ovarian, Liver, etc. In 2018, Roche achieved good growth in both the divisions and delivered therapies like Xofluza (baloxavir marboxil) for influenza and targets serious diseases like cancer, multiple sclerosis, & hemophilia.
*Companies listed above are based on oncology segment revenue. Celgene and BMS
oncology segment revenue has been taken prior to acquisition.